$IMMX News

HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $20

What's Going On With Immix Biopharma Stock Thursday?

Immix Biopharma Prices Underwritten Registered Offering Of 16,778,524 Shares At $8.94 Per Share

Immix Biopharma Announces That All Four Relapsed/Refractory Al Amyloidosis MRDd-Negative Patients Presented At ASH 2025 Have Converted To Complete Response

HC Wainwright & Co. Reiterates Buy on Immix Biopharma, Maintains $15 Price Target

Mizuho Maintains Outperform on Immix Biopharma, Raises Price Target to $15

Immix Biopharma Announces Achieved Enrollment Targets For NEXICART-2 AL Amyloidosis Treatment Study; Results Expected Q3 2026

Immix Biopharma Announces Achieved Enrollment Targets For NEXICART-2 AL Amyloidosis Treatment Study; Results Expected Q3 2026

Citizens Reiterates Market Outperform on Immix Biopharma, Maintains $23 Price Target

HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $15

Immix Biopharma Q4 EPS $(0.28) Misses $(0.16) Estimate

Morgan Stanley Initiates Coverage On Immix Biopharma with Overweight Rating, Announces Price Target of $20

Citizens Initiates Coverage On Immix Biopharma with Market Outperform Rating, Announces Price Target of $23

Mizuho Initiates Coverage On Immix Biopharma with Outperform Rating, Announces Price Target of $14

Immix Biopharma Granted Breakthrough Therapy Designation From FDA To NXC-201 To Treat Relapsed/Refractory AL Amyloidosis

Immix Biopharma (IMMX) Shares Slip As Investors Focus On Plans To Offer And Sell $750 Million In Securities

Immix Biopharma To Offer And Sell Up To $750M In Securities

Immix Biopharma: Thesis Playing Out; Thoughts On Valuation And Competition

Immix Biopharma shares are trading higher after HC Wainwright & Co. raised the price target from $8 to $12.

HC Wainwright & Co. Maintains Buy on Immix Biopharma, Raises Price Target to $12